Results 71 to 80 of about 7,843 (191)

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula, Ednan K. Bajwa, Alexandra G. Cornell, Maria Jose Loureiro, Samuel S. Kim, Julia Richmond DiBello, Eric Sterner, Richard Chen, Islam R. Younis   +8 more
wiley   +1 more source

Ischemic Preconditioning and Iloprost Reduces Ischemia-Reperfusion Injury in Jejunal Flaps: An Animal Model [PDF]

, 2019
Background: Free jejunal flaps are among the most commonly used flaps for esophageal reconstruction. However, ischemia-reperfusion injury caused by warm ischemia seen during transfer limits their use.

core   +1 more source

Evidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that
Scott A. Barman, Zsuzsanna Bordan, David J. R. Fulton   +2 more
wiley   +1 more source

Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. The same treatment is recommended in patients with PAH associated with connective tissue disease (CTD) and idiopathic PAH (IPAH). However, the effectiveness of PAH‐specific treatment in these both groups is inconsistent.
Anna Smukowska‐Gorynia, Sylwia Iwańczyk, Michał Ciurzyński, Marcin Waligóra, Marcin Kurzyna, Piotr Pruszczyk, Grzegorz Kopeć, Katarzyna Mizia‐Stec, Ilona Skoczylas, Łukasz Chrzanowski, Piotr Błaszczak, Katarzyna Ptaszyńska, Grzegorz Grześk, Ewa Malinowska, Małgorzata Peregud‐Pogorzelska, Michał Tomaszewski, Ewa Mroczek, Miłosz Jaguszewski, Ewa Lewicka, Katarzyna Widejko, Agnieszka Pawlak, Wojciech Jacheć, Zbigniew Gąsior, Katarzyna Betkier‐Lipińska, Judyta Winowska‐Józwa, Marta Banaszkiewicz, Tatiana Mularek‐Kubzdela   +26 more
wiley   +1 more source

Inhaled iloprost for digital necrosis in systemic sclerosis – an effective alternative

European Journal of Case Reports in Internal Medicine
Introduction: Vascular issues in systemic sclerosis (SSc), notably Raynaud’s phenomenon, can lead to digital ulcers (DU) and necrosis, causing pain and infections. Intravenous prostacyclin (iloprost) is used for established DUs.
Jaouad Yousfi, Soukaina Alami Idrissi, Fatima Dakir, Zineb Bott, Chadyne Taouil, Mouna Zahlane, Lamiaa Essaadouni   +6 more
doaj   +1 more source

Iloprost for the treatment of Frostbite

, 2023
A scoping review that aims to map the current evidence regarding the use of iloprost to treat ...
Dunavan Morris-Janzen, Alex Poole, Josianne Gauthier   +2 more
core   +1 more source

Prostacyclin Inhibits Non-Small Cell Lung Cancer Growth by a Frizzled 9-Dependent Pathway That Is Blocked by Secreted Frizzled-Related Protein 1

Neoplasia: An International Journal for Oncology Research, 2010
The goal of this study was to assess the ability of iloprost, an orally active prostacyclin analog, to inhibit transformed growth of human non-small cell lung cancer (NSCLC) and to define the mechanism of iloprost's tumor suppressive effects.
Meredith A. Tennis, Michelle Van Scoyk, Lynn E. Heasley, Katherine Vandervest, Mary Weiser-Evans, Scott Freeman, Robert L. Keith, Pete Simpson, Raphael A. Nemenoff, Robert A. Winn   +9 more
doaj   +1 more source

Inhaled iloprost for the control of pulmonary hypertension

, 2009
Sabine Krug1, Armin Sablotzki2, Stefan Hammerschmidt1, Hubert Wirtz1, Hans-Juergen Seyfarth11University of Leipzig, Department of Respiratory Medicine, Germany; 2Klinikum St.
Stefan Hammerschmidt, Hubert Wirtz, Hans-Juergen Seyfarth, Sabine Krug, Armin Sablotzki   +4 more
core  

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study [PDF]

, 2015
Background Combination therapy is frequently used to treat patients with pulmonary hypertension but few studies have compared treatment regimens. This study examined the long-term effect of different combination regimens of inhaled iloprost and oral ...
Voswinckel, Robert, Ghofrani, H., Richter, M., Ghofrani, H.A., Voswinckel, R. (Robert), Bandorski, Dirk, Ghofrani, H-A, Katrin Milger, Sommer, N., Grimminger, F., Richter, M.J. (Manuel), Henning Gall, Natascha Sommer, Bandorski, D. (Dirk), Manuel J. Richter, Seeger, W., Seeger, Werner, Milger, Katrin, Richter, Manuel J., Ghofrani, Hossein-Ardeschir, Voswinckel, R, Milger, K. (Katrin), Gall, H., Gall, Henning, Werner Seeger, Friedrich Grimminger, Gall, H, Sommer, Natascha, Grimminger, Friedrich, Seeger, W, Voswinckel, R., Milger, K., Bandorski, D., Milger, K, Robert Voswinckel, Sommer, N, Richter, MJ, Bandorski, D, Dirk Bandorski, Grimminger, F, Seeger, W. (Werner), Gall, H. (Henning), Grimminger, F. (Friedrich), Hossein-Ardeschir Ghofrani, Sommer, N. (Natascha)   +44 more
core   +1 more source

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension

Pulmonary Circulation, 2018
Inhaled iloprost efficiently improves pulmonary hemodynamics, exercise capacity, and quality of life in patients with pulmonary arterial hypertension (PAH). However, the process of inhalation is laborious for patients suffering from resting dyspnea.
Kazuhiko Nakayama, Noriaki Emoto, Naoki Tamada, Mitsumasa Okano, Yuto Shinkura, Kenichi Yanaka, Hiroyuki Onishi, Mana Hiraishi, Shinichiro Yamada, Hidekazu Tanaka, Toshiro Shinke, Ken-ichi Hirata   +11 more
doaj   +1 more source